Scancell Holdings

Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects. Its ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system, where inflammation is stimulated at the tumor site and the cytotoxic T-lymphocyte response, where immune system cells are primed to recognize and kill specific cells. The Moditope immunotherapy platform is based on exploiting the normal immune response to stressed cells, mediated by cluster of differentiation 4+ T cells, and harnessing this mechanism to eradicate cancer cells.
Company Growth (employees)
Type
Public
HQ
Nottingham, GB
Size (employees)
10 (est)
Scancell Holdings is headquartered in Nottingham, GB

Scancell Holdings Office Locations

Scancell Holdings has an office in Nottingham
Nottingham, GB (HQ)
Department of Clinical Oncology City Hospital Hucknall Road

Scancell Holdings Metrics

Scancell Holdings Market Value History

Scancell Holdings Online Presence

Scancell Holdings Company Life

You may also be interested in